Author(s): Aziz dayoub, Mohammad Imad Khayat, Afraa Zrieki

Email(s): azizdayoub1992@gmail.com

DOI: 10.52711/0974-360X.2023.00036   

Address: Aziz dayoub1, Mohammad Imad Khayat2, Afraa Zrieki3
1Biochemistry and Microbiology Department, Faculty of Pharmacy, Tishreen University, Latakia, Syria.
2Laboratory Medicine Department, Faculty of Medicine, Tishreen University, Lattakia, Syria.
3Pharmaceutics and Pharmaceutical Technology Department, Faculty of Pharmacy, Tishreen University, Latakia, Syria.
*Corresponding Author

Published In:   Volume - 16,      Issue - 1,     Year - 2023


ABSTRACT:
High sensitivity C-reactive protein (Hs-CRP) is a sensitive marker of subclinical inflammation associated with atherosclerosis. Uncontrolled diabetes mellitus (DM) is one of the important risk factors of coronary heart disease (CHD). The aim of this study was to evaluate the association between Hs-CRP levels and both glycaemic control and CHD in Syrian type 2 diabetes mellitus (T2DM) patients. A random sample of 108 subjects was selected from T2DM and/or CHD patients seen in the National Centre for Diabetes, and the outpatient clinic of cardiology department at Tishreen University Hospital in Latakia. Four groups were formed: Group 1 [T2DM (+) CHD (-), N=29], Group 2 [T2DM (-) CHD (+), N=25], Group 3 [T2DM (+) CHD (+), N=29], and Group 4 (T2DM (-) CHD (-), N=25). Serum Hs-CRP and glycated haemoglobin (HBA1C) were determined. The SPSS 25.0 program was used for the statistical analysis. Probability (P) value less than 0.05 was considered statistically significant. Mean Hs-CRP level was higher in T2DM subjects with (5.23±1.56mg/l) or without (2.29±0.78mg/l) CHD compared to T2DM (-) CHD (-) patients (0.16±0.04mg/l), (p<0.0001 for both). Mean Hs-CRP level in T2DM with CHD was not only higher than T2DM patients without CHD (p<0.0001), but also than non-diabetic subjects with CHD (2.56±0.45mg/l) (p<0.0001). There was a positive correlation between serum Hs-CRP and HBA1C in T2DM patients with CHD (r=0.781, P<0.0001), Similarly, Hs-CRP levels were positively and significantly correlated with HBA1C in T2DM patients without CHD (r=0.800, p<0.0001). We also noticed that for every 1.0% increase in HbA1c there was an 77% increase in the likelihood of having an elevated Hs-CRP. We concluded that Hs-CRP was strongly correlated with glycaemic control in T2DM patients. The highest Hs-CRP level was observed in T2DM with CHD patients. Hs-CRP could predict the incidence of coronary heart disease in T2DM patients.


Cite this article:
Aziz dayoub, Mohammad Imad Khayat, Afraa Zrieki. Association of High sensitivity C-reactive protein (Hs-CRP) with poor Glycaemic control and Coronary Heart Disease in Type 2 Diabetes Mellitus. Research Journal of Pharmacy and Technology 2023; 16(1):193-9. doi: 10.52711/0974-360X.2023.00036

Cite(Electronic):
Aziz dayoub, Mohammad Imad Khayat, Afraa Zrieki. Association of High sensitivity C-reactive protein (Hs-CRP) with poor Glycaemic control and Coronary Heart Disease in Type 2 Diabetes Mellitus. Research Journal of Pharmacy and Technology 2023; 16(1):193-9. doi: 10.52711/0974-360X.2023.00036   Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-1-36


REFERENCES:
1.    Abinaya, S. and V.M. Aanandhi, An improvement in patient compliance in diabetes mellitus. Research Journal of Pharmacy and Technology, 2018. 11(2): p. 587-592. DOI: 10.5958/0974-360X.2018.00108.7
2.    Ibrahim, R., M.I. Khayat, and A. Zrieki, D Hypovitaminosis in Syrian Type 2 Diabetes Mellitus Patients: Lack of Relationship with Glycemic Control. Research Journal of Pharmacy and Technology, 2018. 11(12): p. 5319-5326. DOI: 10.5958/0974-360X.2018.00968.X
3.    Ambad, R., et al., Association of leptin in diabetes mellitus and obesity. Research Journal of Pharmacy and Technology, 2020. 13(12): p. 6295-6299. DOI: 10.5958/0974-360X.2020.01095.1
4.    Rao, U.M., et al., Cross-Sectional Study on Knowledge, Attitude and Practice regarding Diabetes mellitus among Medical and Non-Medical Students. Research Journal of Pharmacy and Technology, 2018. 11(11): p. 4837-4841. DOI: 10.5958/0974-360X.2018.00879.X
5.    Kalaivanan, S., et al., Clinical Assessment and Comparison of Lipid Profiles among Coronary Artery Disease and type 2 Diabetes Mellitus Patients receiving Statin Therapy. Research Journal of Pharmacy and Technology, 2017.10(1):p.18. DOI:10.5958/0974-360X.2017.00005.1
6.    Gaur, A., et al., Drug utilization evaluation of coronary artery disease in a tertiary care hospital in Punjab. Research Journal of Pharmacy and Technology, 2019. 12(1): p. 149-155. DOI: 10.5958/0974-360X.2019.00028.3
7.    Abraham, M.M., et al., Comparison of four screening methods for diabetic peripheral neuropathy in type 2 diabetes mellitus patients: a cross sectional study. Research Journal of Pharmacy and Technology, 2018. 11(12): p. 5551-5558.DOI:10.5958/0974-360X.2018.01010.7
8.    Geetha, P. and P. Shanmugasundaram, A Prospective Observational Study on assessment of risk factor associated with diabetic retinopathy in patients diagnosed with type 2 Diabetes Mellitus in south Indian population. Research Journal of Pharmacy and Technology, 2019. 12(2): p. 595-599. DOI: 10.5958/0974-360X.2019.00106.9
9.    Mounika, V., et al., A prospective study on incidence of Anaemia in type 2 Diabetes Mellitus Patients. Research Journal of Pharmacy and Technology, 2017. 23: p. 20.53. DOI: 10.5958/0974-360X.2017.00003.8  
10.    Cusick, M., et al., Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care, 2005. 28(3): p. 617-625. DOI: 10.2337/diacare.28.3.617
11.    Seo, Y.-H. and H.-Y. Shin, Relationship between hs-CRP and HbA1c in Diabetes Mellitus Patients: 2015–2017 Korean National Health and Nutrition Examination Survey. Chonnam medical journal, 2021. 57(1): p. 62. doi: 10.4068/cmj.2021.57.1.62
12.    Park, J.Y., M.J. Kim, and J.H. Kim, Influence of Alcohol Consumption on the Serum hs-CRP Level and Prevalence of Metabolic Syndrome-Based on the 2015 Korean National Health and Nutrition Examination Survey. Journal of the Korean Dietetic Association, 2019. 25(2): p. 83-104. doi: wpr-766387
13.    Herder, C., M. Carstensen, and D. Ouwens, Anti‐inflammatory cytokines and risk of type 2 diabetes. Diabetes, Obesity and Metabolism, 2013. 15(s3): p. 39-50. doi.org/10.1111/dom.12155
14.    Elimam, H., A.M. Abdulla, and I.M. Taha, Inflammatory markers and control of type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research and Reviews, 2019. 13(1): p. 800-804. doi: 10.1016/j.dsx.2018.11.061
15.    Badimon, L., et al., C-reactive protein in atherothrombosis and angiogenesis. Frontiers in immunology, 2018. 9: p. 430. doi: 10.3389/fimmu.2018.00430
16.    Ridker, P.M., Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation, 2003. 107(3): p. 363-369. DOI: 10.1161/01.cir.0000053730.47739.3c
17.    Pearson, T.A., et al., Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. circulation, 2003. 107(3): p. 499-511. DOI: 10.1161/01.cir.0000052939.59093.45
18.    Cavero-Redondo, I., et al., Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis. BMJ open, 2017. 7(7): p. e015949. DOI: 10.1136/bmjopen-2017-015949
19.    Cohen, M.P., J. Witt, and V.Y. Wu, Purified haemoglobin preparations in the evaluation of HbA1c determination by ion exchange chromatography. Ann Clin Biochem, 1993. 30 ( Pt 3): p. 265-71. DOI: 10.1177/000456329303000307
20.    King, D.E., et al., C-reactive protein and glycemic control in adults with diabetes. Diabetes care, 2003. 26(5): p. 1535-1539. DOI: 10.2337/diacare.26.5.1535
21.    Tracy, R.P., Inflammation, the metabolic syndrome and cardiovascular risk. International journal of clinical practice. Supplement, 2003(134): p. 10-17. doi: 10.1016/j.mehy.2003.12.014.
22.    Haverkate, E., et al., Production of C-reactive protein and risk of coronary events in stable and unstable angina. The Lancet, 1997. 349(9050): p. 462-466. DOI: 10.1016/s0140-6736(96)07591-5
23.    Asegaonkar, S.B., et al., High-sensitivity C-reactive protein: a novel cardiovascular risk predictor in type 2 diabetics with normal lipid profile. Journal of Diabetes and its Complications, 2011. 25(6): p. 368-370. DOI: 10.1016/j.jdiacomp.2011.10.001
24.    Ridker, P.M., et al., Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England journal of medicine, 2002. 347(20): p. 1557-1565. DOI: 10.1056/NEJMoa021993
25.    Koenig, W., C‐reactive protein and cardiovascular risk: an update on what is going on in cardiology. Nephrology Dialysis Transplantation, 2003. 18(6): p. 1039-1041. https://doi.org/10.1093/ndt/gfg103
26.    Mohieldein, A.H., M. Hasan, and M.I. El-Habiby, High Sensitivity C-Reactive Protein as Atherogenic Marker Among Type 2 Diabetes. Eur Sci J, 2017. 33(13): p. 403. DOI: https://doi.org/10.19044/esj.2017.v13n33p403
27.    Lima, L.M., et al., High-sensitivity C-reactive protein in subjects with type 2 diabetes mellitus and/or high blood pressure. Arquivos brasileiros de endocrinologia and metabologia, 2007. 51: p. 956-960. DOI: 10.1590/s0004-27302007000600010
28.    Haffner, S.J. and H. Cassells, Hyperglycemia as a cardiovascular risk factor. The American journal of medicine, 2003. 115(8): p. 6-11. DOI: 10.1016/j.amjmed.2003.09.009
29.    Gore, M.O., et al., Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges. Current cardiology reports, 2015. 17(7): p. 1-9. DOI: 10.1007/s11886-015-0607-7
30.    Haffner, S.M., et al., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England journal of medicine, 1998. 339(4): p. 229-234. DOI: 10.1056/NEJM199807233390404
31.    Stern, M.P., Diabetes and cardiovascular disease: the “common soil” hypothesis. Diabetes, 1995. 44(4): p. 369-374. https://doi.org/10.2337/diab.44.4.369
32.    Fukuhara, M., et al., Hyperglycemia promotes microinflammation as evaluated by C-reactive protein in the very elderly. Internal Medicine, 2007. 46(5): p. 207-212. DOI: 10.2169/internalmedicine.46.1868
33.    Gustavsson, C.G. and C.-D. Agardh, Markers of inflammation in patients with coronary artery disease are also associated with glycosylated haemoglobin A1c within the normal range. European heart journal, 2004. 25(23): p. 2120-2124. DOI: 10.1016/j.ehj.2004.09.008
34.    Baig, M., K.N. Sarwari, and T. Sabeer, Study of serum hs-crp in Type 2 diabetic patients. Int J Basic Appl Med Sci, 2013. 3(3): p. 230-40. Corpus ID: 38105365
35.    Bahceci, M., et al., Is serum C-reactive protein concentration correlated with HbA 1c and insulin resistance in Type 2 diabetic men with or without coronary heart disease? Journal of endocrinological investigation, 2005. 28(4): p. 145-150. DOI: 10.1007/BF03345357
36.    Sargowo, D., The Importance of Managing HbA1c in Coronary Artery Disease: Keep It Low. Heart Science Journal, 2020. 1(3): p. 1-3. DOI: https://doi.org/10.21776/ub.hsj.2020.001.03.1
37.    Bahceci, M., et al., Is serum C-reactive protein concentration correlated with HbA1c and insulin resistance in Type 2 diabetic men with or without coronary heart disease? Journal of endocrinological investigation, 2005. 28(4): p. 145-150. DOI: 10.1007/BF03345357
38.    Amanullah, S., et al., Association of hs-CRP with diabetic and non-diabetic individuals. Jordan Journal of Biological Sciences (JJBS), 2010. 3(1): p. 7-12. doi: 10.7860/JCDR/2014/8085.4522
39.    Shi, C.H., et al., Associations among glycemic excursions, glycated hemoglobin and high-sensitivity C-reactive protein in patients with poorly controlled type 2 diabetes mellitus. Experimental and Therapeutic Medicine, 2015. 10(5): p. 1937-1942. DOI: 10.3892/etm.2015.2730
40.    Bandyopadhyay, R., et al., Study of c reactive protein in type 2 diabetes and its relation with various complications from Eastern India. Journal of Applied Pharmaceutical Science, 1930. 3(7): p. 156-159. DOI: 10.7324/JAPS.2013.3729
41.    Ahmad, J., et al., Inflammatory markers, insulin resistance and carotid intima-media thickness in North-Indian type 2 diabetic subjects. Japi, 2007. 55: p. 693-698. doi: 55:693-9.
42.    Tanaka, S.I., et al., T lymphopaenia in relation to body mass index and TNF‐α in human obesity: adequate weight reduction can be corrective. Clinical endocrinology, 2001. 54(3): p. 347-354. https://doi.org/10.1046/j.1365-2265.2001.1139cn2155.x
43.    Mezher, M.N. and D.H.A. Jawad, Evaluation of tumor necrosis factor-alpha in hepatitis C virus with diabetes mellitus and non diabetes mellitus patients. Research Journal of Pharmacy and Technology, 2017. 10(10): p. 3260-3263. DOI: 10.5958/0974-360X.2017.00578.9  
44.    Bhattacharya, K., et al., Pathophysiology of obesity: endocrine, inflammatory and neural regulators. Research Journal of Pharmacy and Technology, 2020. 13(9): p. 4469-4478. DOI: 10.5958/0974-360X.2020.00789.1
45.    Kern, L., et al., Obesity-induced TNFα and IL-6 signaling: the missing link between obesity and inflammation—driven liver and colorectal cancers. Cancers, 2018. 11(1): p. 24. DOI: 10.3390/cancers11010024
46.    Ford, E.S., Body mass index, diabetes, and C-reactive protein among US adults. Diabetes care, 1999. 22(12): p. 1971-1977. DOI: 10.2337/diacare.22.12.1971
47.    Mankowska, A., J. Pollak, and G. Sypniewska, Association of C-reactive protein and other markers of inflammation with risk of complications in diabetic subjects. Ejifcc, 2006. 17(1): p. 8. DOI: eJIFCC2006Vol17No1pp008-011
48.    D’Alessandris, C., et al., C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser 307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia, 2007. 50(4): p. 840-849. DOI: 10.1007/s00125-006-0522-y
49.    Campos, S. and H. Baumann, Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Molecular and cellular biology, 1992. 12(4): p. 1789-1797. DOI: 10.1128/mcb.12.4.1789-1797.1992
50.    Al-jebory, A.M. and H.A. Al-zubeidi, Relationship between hs-C-reactive protein and some biochemical variables in Cardiovascular and Type-2-Diabetic Mellitis patients. Journal of University of Babylon, 2014. 22(4). doi: 10.7860/JCDR/2017/30272.10528
51.    Chu, N.V., et al., Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care, 2002. 25(3): p. 542-549. doi: 10.2337/diacare.25.3.542

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available